J&J: Potential HIV vaccine falls short in mid-stage study

J&J: Potential HIV vaccine falls short in mid-stage study

A potential HIV vaccine being developed by Johnson & Johnson did not provide protection against the virus in a mid-stage study, the drugmaker said Tuesday.

Leave a Reply

Your email address will not be published. Required fields are marked *